T-061 P.005/006 F-655

Application No.: 10/050050 Docket No.: JJJ-P05-518

AMENDMENTS TO THE CLAIMS

1.-68. (Cancelled)

- 69. (Currently amended) A method for limiting the mitogenic activity of proliferating epithelial cells in a mammal in need thereof, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with said epithelial cells, wherein said morphogen:
 - (i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 38-139 of SEQ ID NO: 5;
 - (ii) is not TGFβ2; and
 - (iii) is capable of inhibiting lesion formation in an in vivo oral mucositis assay, so as to thereby limit the mitogenic activity of said cells in said mammal.
- (Previously presented) The method of claim 69, wherein said epithelial cells are epidermal skin cells.
- 71. (Previously presented) The method of claim 70, wherein proliferation of said cells is associated with psoriasis.
- 72. (Previously presented) A method for inhibiting scar tissue formation at a site of tissue damage in a mammal, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with cells at a site of tissue damage in the mammal, wherein said morphogen:
 - (i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-I, residues 38-139 of SEQ_ID NO: 5;
 - (ii) is not TGFβ2; and
 - (iii) is capable of inhibiting lesion formation in an in vivo oral mucositis assay, so as to thereby inhibit scar tissue formation at a site of tissue damage in said mammal.

73. (Cancelled)